Evidence map›Paper›PMID 42898461›Full record

ArticleEULAR rheumatology open2026

Sex-specific outcomes in methotrexate therapy among patients with psoriatic arthritis and psoriasis.

Liana Barenbrug, Gonul Hazal Koc, Marisol E Otero, Emmerik F A Leijten, Sander I van Leuven, Irene E van der Horst-Bruinsma, Juul M P A van den Reek, Elke M G J de Jong, Marc R Kok, Marijn Vis and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liana BarenbrugDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Gonul Hazal KocDepartment of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
Marisol E OteroDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Emmerik F A LeijtenDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Sander I van LeuvenDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Irene E van der Horst-BruinsmaDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Juul M P A van den ReekDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Elke M G J de JongDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Marc R KokDepartment of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands.
Marijn VisDepartment of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
Michelle L M MulderDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The purpose of this paper is to identify sex-specific patterns in methotrexate (MTX) therapy among patients with psoriatic arthritis (PsA) and psoriasis (PsO). Methods: Data from adult patients treated with MTX monotherapy included in the Dutch southwest Early Psoriatic Arthritis Registry (rheumatology) or Continuous Assessment of Psoriasis Treatment Use REgistry with Methotrexate (dermatology) registries were obtained to create 2 cohorts of patients with PsA or PsO, respectively. Drug survival was assessed using Kaplan-Meier and Cox regression analyses. Disease activity, dosing, adverse events, and subsequent treatments were evaluated. Results: A total of 525 (50.1% female) patients were included in the PsA cohort and 217 (41.1% female) patients in the PsO cohort. In the PsA cohort, female sex was associated with shorter drug survival (adjusted hazard ratio [HR] = 2.5; 95% CI, 1.6-4.1; Conclusions: Drug survival and treatment response of MTX vary between PsA and PsO, with females in the PsA cohort while males in the PsO cohort having worse outcomes.

Identifiers

PMID42898461
PMCPMC13678078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.